Skip to main content
. 2014 Nov 3;9(1):35–42. doi: 10.3892/ol.2014.2662

Figure 1.

Figure 1

MGMT mRNA expression levels and DNA methylation status in laryngeal carcinoma HEp-2 cells before and after treatments with Aza and TSA. (A) RT-qPCR analysis of MGMT mRNA expression in laryngeal carcinoma HEp-2 before (Ctrl) and after treatment with Aza and/or TSA. (B) Methylation-specific PCR analysis of DNA methylation at the MGMT promoter region in laryngeal carcinoma HEp-2 cells before and after treatment with Aza and/or TSA. Lane M, methylated alleles (121 bp); lane U, unmethylated alleles (122 bp); Pos, positive control; Neg, negative control. A minimum of three independent experiments were performed, which all produced similar results. MGMT, O6-methylguanine-DNA methyltransferase; Ctrl, control; TSA, trichostatin A; Aza, 5-aza-2′-deoxycytidine; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.